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Tbjectives: The most important predictors for failure of the maze procedure are long
tanding atrial fibrillation (AF), rheumatic heart disease (RHD), and enlarged atria.
t is well documented, however, that some patients have recurrence of atrial
rrhythmia only late in follow-up. The aims of this study are to assess the effec-
iveness of the maze procedure and late cardioversion (pharmacologic or electrical)
n patients wtih an increased risk for procedure failure.
atients and Methods: Fifty-five patients with AF, enlarged left atrium (5 cm),
nd/or RHD were enrolled in the study. Cryosurgery was performed on all patients
nd was combined with bipolar radiofrequency in the last four patients. The lesion
attern resembles the maze procedure. A follow-up was completed on all patients
24.5  9.6 months with a range of 3-39 months).
esults: The operative mortality was 3.7% (2 patients), both deaths unrelated to the
aze procedure. Ninety-eight percent of patients were free of AF upon discharge,
ith an 11% incidence of early pacemaker implantation. In the first three months
ostoperatively, 53% of the patients experienced intermittent atrial arrhythmia. Four
atients were recorded with permanent AF in late follow-up. The only predictor for
ate AF (3 months of follow-up) was perioperative AF. Atrial size, RHD, and AF
uration did not predict late failure.
onclusions: The maze procedure can be applied with high success rate in patients
ith RHD, enlarged atria, and long-standing AF. In our experience many of the late
ecurrences were recorded late in the follow-up and were treated successfully with
ntiarrhythmic drugs and/or cardioversion. Therefore a close follow-up is required
o enhance the success rate of the procedure.
 
he maze procedure is recognized as the most effective surgical procedure to
treat all types of atrial fibrillation (AF), with a reported long-term success
rate in excess of 90%.1,2 Recent reports clearly show that the success rate
ay be significantly lower in a subgroup of patients with longstanding AF, enlarged
eft atrium, and rheumatic heart disease (RHD).3-5 It is reported that some patients
xperience recurrence of atrial arrhythmias only late in the follow-up phase.3 The
ommon practice in such instances is to not take any action in an effort to restore
inus rhythm because the procedure has likely failed. However, in many cases this
ssumption is not valid. On the basis of other reports, it is important to make every
ffort to restore sinus rhythm and improve the long-term outcome of these pa-
ients.6-8 The aims of this study were to assess (1) the effectiveness of the maze
rocedure in a group of patients, all of whom had at least 1 traditional risk factor for
rocedural failure, and (2) the efficacy of a late intervention to reestablish sinus
hythm using antiarrhythmic drugs and/or cardioversion.



































































































ifty-five patients with AF, RHD, and/or left atrial size larger than
 cm were enrolled in the study (Tables 1 and 2). The surgical
blation protocol was based on the Maze III lesion pattern. The
nly modification that was applied to the Maze III procedure was
round the pulmonary veins. Instead of the box lesion around the
ulmonary veins, we isolated the right and left pulmonary veins
nd then applied the connecting lesion between the right and left
nferior pulmonary veins (Maze IV).9 In this study we used the
ryotechnology by Cooper Surgical (Shelton, Conn) as the only
blative technology in all patients except for the last 4 in whom we
ombined it with bipolar radiofrequency ablation by AtriCure, Inc
Cincinnati, Ohio).
The maze procedure was performed only if patients had a
istory of AF (continuous or intermittent) for more than 3 months.
he procedure was performed as an isolated procedure in only 2
atients; therefore, the majority of the patients in this series had
nother indication for open surgery in addition to AF. A mean
ollow-up of 24.5  9.6 months (3-39 months) was completed for
he entire group of patients. The end points for the study were
ortality and major morbidity events, atrial arrhythmia, the use of
ntiarrhythmic drugs late in the follow-up phase, and repeated
urgical procedures. Events recorded during the first 3 months
ostoperatively were defined as “early events,” and those recorded
ater were defined as “late events.”
Forty-eight patients had at least 1 Holter monitoring during
heir follow-up. Otherwise, rhythm was recorded every 3 months
sing repeated electrocardiogram strips.
ntiarrhythmic Treatment and Management of
ecurrent Arrhythmia
n general, there is no clear policy to guide the use of antiarrhyth-
ic drugs in patients after the maze procedure. Our policy is based
ABLE 1. Patients’ characteristics
ge (y) (median, range) 59.4 11.6 (59, 39-77)
emale (%) 58.2
ermanent AF (%) 67.3
uration (y) (range) 5.7 5.0 (0.25-25)
ersistent or paroxysmal AF (%) 32.7
uration (y) (range) 3.8 3.5 (0.25-10)
heumatic heart disease (%) 67.3
ean left atrial diameter (cm)
(median, range)
6.3  0.8 (6.4, 5.2-9.1)
oncomitant surgical procedure (%) 96
epeated surgery (%) 16.4
verage follow-up (mo)
(median, range)
24.5 9.6 (27, 3-39)
Abbreviations and Acronyms
AF  atrial fibrillation
OR  odds ratio
RHD rheumatic heart diseasemF, atrial fibrillation.
074 The Journal of Thoracic and Cardiovascular Surgery ● Man our experience with patients and is as follows (Figure 1).
atients with a history of permanent AF, an enlarged left atrium,
nd history of RHD are discharged from the hospital with antiar-
hythmic drug treatment for 3 months. Amiodarone and sotalol are
he drugs of choice. After this 3-month period the drug should be
iscontinued, and follow-up of the heart rhythm should be con-
ucted using a Holter monitor. If a patient fails to maintain sinus
hythm, we resume antiarrhythmic treatment and attempt electrical
ardioversion if required.
The type of antiarrhythmic drug was changed only if a patient
xperienced a recurrence of arrhythmia while treated accurately
ith a given drug. Electrical cardioversion was offered to patients
ho failed to maintain sinus rhythm even if they were late in the
ollow-up. The first attempt was performed without any changes in
he oral antiarrhythmic drug treatment or after a loading dose of
miodarone (if a given patient was not taking any antiarrhythmic
edication).
In case of recurrent atrial arrhythmia, we tried 2 different
ntiarrhythmic drug regimens and 3 different attempts of electrical
ardioversion before stating a procedural failure. We attempted
ate control on all our patients who did not maintain sinus rhythm
ith the use of beta- and calcium-blockers.
tatistical Analysis
ata were collected in Microsoft Excel (Microsoft Co, Redmond,
ash) and analyzed in Statistical Analysis Software (Version
.02, Cary, NC). Continuous data are expressed as mean  stan-
ard deviation. Categoric data are expressed as frequency and
ercentage. Unconditional logistic regression was used to examine
redictors of recurrent AF and are reported as odds ratios (OR) and
5% confidence intervals. The maximum number of predictor vari-
bles in any of the multivariate analysis was restricted to 6 (as
uggested by the cumulative rule of no more than 10 subjects per
odeled predictor). Kaplan-Meier estimates were used to depict free-
om from permanent atrial arrhythmia. Because of the population-
ased nature of this study, no power analysis was attempted. Given
he low event rate and long-term follow-up required, our center
ould most likely never meet the calculated sample size require-
ents. A decision was made to present our findings as soon as a
elatively large number of patients were seen and followed for a






aze only 2 3.6
aze  MVR 17 31
aze  MVR  tricuspid valve surgery 16* 29
aze  MV repair 4 7.3
aze  CABG 2 3.6
aze  CABG  valve surgery 5 9.1
aze  AVR 4 7.3
aze  AVR  MVR 5** 9.1
VR, Mitral valve replacement; MV, mitral valve; CABG, coronary artery
ypass graft; AVR, aortic valve replacement. *Tricuspid valve repair  15,
ricuspid valve replacement  1. **Combined with tricuspid valve
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CDesults
nstitutional board review approval for the study was obtained.
ortality and Major Morbidity Events
he operative mortality was 3.7% (2 patients); therefore, 53
atients entered the follow-up phase. No late mortality was
ecorded during the follow-up.
epeated Surgical Intervention
evere tricuspid insufficiency developed in 1 patient who
nderwent the maze procedure combined with mitral valve
eplacement, necessitating tricuspid valve repair 15 months
fter the original procedure. Significant left anterior de-
cending artery stenosis (the left anterior descending artery
as not bypassed during the surgery) developed in 1 patient
ho had a combined procedure of redo coronary artery
Discontinue
At Discharge 




3 months follow-up 
(Holter ECG)
Sinus Rhythm ?
Sinus Rhythm ? 
Figure 1. Arrhythmia follow-up and treatment in patie
DC shock, electrical cardioversion; ECG, electrocardioypass grafting, mitral valve replacement, tricuspid valve p
The Journal of Thoracicepair, and the maze procedure, necessitating a stent im-
lantation to the left anterior descending artery.
ecurrence of Atrial Arrhythmia
ecurring atrial arrhythmia after the maze procedure is not
lways AF. There are cases of atrial flutter alone, combined
F and atrial flutter, and atrial tachycardia.10 In this study
e refer to events of recurrence as atrial arrhythmia. Atrial
rrhythmia recorded during the first 3 months postopera-
ively is considered early, and events recorded later are
ocumented as late atrial arrhythmia.
Ninety-eight percent of the patients were free of AF on
ospital discharge. Six patients (11%) had a pacemaker
mplantation before hospital discharge for sinus node dys-
unction and bradycardia requiring atrial pacing. Fifty-three
AD1 ± DC Shock
AAD2 ± DC Shock
AAD3 ± DC Shock




fter the maze procedure. AAD, Antiarrhythmic drug;
.A
nts a
gramercent (28) of the patients experienced atrial arrhythmia
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CD uring the first 3 months after surgery. All of them were
reated successfully either with antiarrhythmic drugs alone
21 patients) or a combination of antiarrhythmic drugs and
lectrical cardioversion (7 patients).
ate Atrial Arrhythmia
he median time to experience late AF was 4.5 months for
emales and 10.5 months for males (P  .025). Seventeen
atients experienced 28 events of intermittent AF (persistent
r paroxysmal AF), and all except 1 converted back to sinus
hythm with medications and/or cardioversion. Antiarrhyth-
ic drug therapy as the only treatment was successful in 5
vents, and a combination of drug therapy and cardioversion
as successful in 22 events. Of the 22 events, 9 were treated
ith a single drug and 1 electrical cardioversion session, 7
ere treated with a single drug and 2 electrical cardiover-
igure 2. Atrial arrhythmia during follow-up. Total number of
ABLE 3. Univariate predictors of any recurrent atrial
rrhythmia (>3 months)
arameter OR 95% CI
Statistical
significance
ge (y) 1.02 0.97-1.07 NS
emale 0.81 0.34-1.91 NS
trial size (cm) 1.56 0.69-3.52 NS
HD 5.85 0.66-55.92 NS
reoperative stroke 0.81 0.08-8.16 NS
HF 0.22 0.04-1.17 NS
AP 1.04 0.47-2.34 NS
edo surgery 2.50 0.36-17.60 NS
erioperative AF (3 mo) 12.21 1.38-107.87 
hronic preoperative AF 2.30 0.54-9.76 NS







R, Odds ratio; CI, confidence interval; RHD, rheumatic heart disease; CHF,
ongestive heart failure; PAP, pulmonary arterial pressure; AF, atrial fibril-
ation; NS, not significant.latients in follow-up (numbers on right).
076 The Journal of Thoracic and Cardiovascular Surgery ● Maion sessions, and 6 were treated by replacement of the
ntiarrhythmic drug and 3 electrical cardioversion attempts.
here was 1 failure in conversion back to sinus rhythm. This
atient was treated with sotalol and 1 electrical cardiover-
ion, after which severe bradycardia and cardiogenic shock
eveloped. After the patient recovered, no attempts of rhythm
ontrol were made, and she is currently in rate-controlled AF.
The only predictor for any late intermittent or permanent
trial arrhythmia (3 months of follow-up) is perioperative
F (Table 3). We also used a set of clinical variables and
ested whether their interaction could predict late recur-
ence. The variables were age, gender, RHD, atrial size,
epeated procedure, type of AF, and duration of AF. In this
tudy none of the interactions were found to be a significant
redictor for recurrence of atrial arrhythmia.
Eighty-five percent of intermittent atrial arrhythmia
vents were recorded during the first year postoperatively
ith no such event recorded in patients with a follow-up
ore than 24 months (Figure 2). In univariate and multi-
ariate models no significant predictor for recurrent inter-
ittent atrial arrhythmia was identified.
Four patients have had a recurrence of permanent atrial
rrhythmia, all but 1 with RHD. All patients but 1 were
reated with our antiarrhythmic protocol, which includes a
ombination of drug therapy and electrical cardioversion.
ne patient was treated with oral amiodarone only because
f his refusal to be electrically cardioverted.
In a univariate model preoperative stroke was found to
e a predictor of late permanent atrial arrhythmia. In a
ultivariate model using 6 clinically relevant parameters
RHD, redo surgery, left atrial size, perioperative AF, du-
ation of preoperative permanent AF, and intermittent AF),
o significant predictors were identified. When left atrial
ize was examined using size categories (5-6 cm; 6-6.9 cm;7
m), no significant atrial size was found to be a predictor of
igure 3. Kaplan-Meier estimates to depict freedom from perma-
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A
CDFigure 2 shows the recurrence of intermittent and per-
anent atrial arrhythmia recurrence. Figure 3 shows the
aplan-Meier estimates for freedom from permanent atrial
rrhythmia after the maze procedure.
ong-Term Use of Antiarrhythmic Drugs
nalysis to find predictors for late use of antiarrhythmic
rugs was performed using the same set of variables. In
nivariate and multivariate models, left atrial size and peri-
perative AF were found to be predictors of long-term
ntiarrhythmic drug treatment (21% for patients with a
ollow-up  24 months). When left atrial size was analyzed
sing size categories (5-6 cm; 6-6.9 cm; 7 cm), only left
trial size greater than 7 cm was found as a significant
redictor for late use of antiarrhythmic drugs.
All patients who were treated with antiarrhythmic drugs
ate in the follow-up are those who experienced late arrhyth-
ia recurrence. As a clinician there is a reluctance to stop
he medication in this special subgroup of patients after
uccessful cardioversion back to sinus rhythm.
iscussion
he maze procedure has become the most successful surgi-
al treatment for medically refractory AF.1,11,12 A subgroup
f patients carry a higher risk for failure even when the
aze procedure is performed adequately. These are patients
ith RHD, enlarged left atrium, and longer duration of
F.3,5,9 It is, however, important to identify the risk factors
or failure of the maze procedure and subsequently adjust
he treatment, even late in the follow-up phase. In this study
e present the results of a group of patients in whom AF is
onsidered very difficult to treat. We are aware that some of
he findings in this study may not be completely in line with
he other reports regarding surgery for AF simply because
f the bias that may be caused by preselecting only high-risk
atients for this report. In our series we did not find any
linically significant predictors for late failure for the fol-
owing reasons: (1) The study group, in general, was com-
osed of patients who are at an increased risk for failure. For
xample, the mean left atrial size was 6.3 cm and 67% of the
atients experienced RHD (Table 1); thus, all patients who
ailed either intermittently or permanently carried at least 1
ecognized risk factor for procedural failure. (2) The series
as small, and the number of events may not have been
ufficient to reach significance.
We caution readers to note that although ORs exceeding
.0 are provocative and highly suggestive of a direction of
agnitude, ORs are only statistically significant when the
onfidence intervals do not contain 1, or unity. Small sam-
le sizes, such as in this study, may lead to larger ORs and
ncreased variances. As a result of these increased vari-
nces, statistical significance is usually not met. l
The Journal of ThoracicHowever, despite this, the significance of this report lies
n the fact that we were able to restore sinus rhythm in most
f the patients who failed late in the follow-up phase. As an
xample, 4 patients had experienced persistent AF during
he second year of the follow-up. Sinus rhythm was restored
n all of them with antiarrhythmic drug treatment and/or
lectrical cardioversion.
An interesting finding in our study is gender differences
n time to late arrhythmia event. On the basis of our patient
opulation, we do not have any explanation for this unique
nding, and we speculate that it may be coincidental.
A better understanding of the mechanism of late failures
f the maze procedure is challenging. The most common
xplanation for late failure is associated with left atrial size.
he basic theory claims that if the left atrium is larger than
cm, then the ablation lines of the maze procedure do not
nterrupt the reentry circuits because they are too far apart.
herefore the procedure fails in a higher percentage of
ases. If this theory is correct, then why do many of the
atients maintain their sinus rhythm until late in the follow-up
nd experience a recurrence of atrial arrhythmia only late in the
ollow-up? One explanation may be that the left atrium con-
inues to dilate after surgery, causing a recurrence of AF.
owever, our experience, as well as the experiences of others,
llustrates the opposite. The left and right atrial sizes are sig-
ificantly reduced after the procedure,13 especially in patients
ho have undergone mitral valve surgery that restored the
unction of the valve.
Another possible explanation for late recurrence of atrial
rrhythmias could be based on a better understanding of the
egree of atrial remodeling and its degree of reversibility at
he time of the maze procedure. AF usually occurs in the
ontext of an atrial substrate produced by alterations in atrial
issue properties referred to as remodeling. Atrial remodeling
as different causes, for example, cardiac disease (congestive
eart failure), cardiac arrhythmia, and other biologic pro-
esses. Two different types of remodeling have been re-
orted in animal models of AF: ionic remodeling, which
ffects cellular electrical properties (shortening of atrial
efractoriness), and structural remodeling, which brings sig-
ificant changes to atrial tissue architecture.14 Long-lasting
pisodes of AF in an animal model are mainly promoted by
onduction disturbances. Repeated episodes of AF result in
hronic atrial stretch, which leads to atrial cellular hyper-
rophy and fibrosis.15
As in this study, the maze procedure is performed in
any patients late in the course of the AF and/or the
alvular heart disease. In this case it is likely that the size of
he atrium only mirrors the degree of atrial tissue remodel-
ng and disease, and that in many cases the process is not
ully reversible.16 Patients do fail the procedure late in the
ollow-up phase because the surgical procedure does not
ead to total reversal of the remodeling process. Some




























































Surgery for Acquired Cardiovascular Disease Ad et al
1
A
CDatients are left with a significant amount of atrial tissue,
hich is more susceptible to arrhythmia, even with a min-
mal challenge.17,18 In light of this, the early and late suc-
ess rates of the maze procedure may be significantly im-
roved by earlier intervention.9,19
This series of patients is very challenging. During the
ollow-up we were especially active in treating patients with
rrhythmia recurrences, even late in the follow-up phase.
hus, we have resumed the antiarrhythmic treatment in
ome patients. A predictor for the use of antiarrhythmic
rugs late in the follow-up is left atrial size, especially larger
han 7 cm. However, it was not a predictor for late failure,
erhaps because of the higher rate of use of antiarrhythmic
rugs late in the follow-up (55%; 5/9 patients with left
trium 7 cm). It is clear now that a subgroup of patients
ith an enlarged left atrium and severely diseased atrial
ubstrate need to receive antiarrhythmic treatment for an
xtended period of time (which cannot be defined as of yet).
s mentioned, a better understanding of the remodeling
rocess may extend our ability to adjust the postoperative
are.
Therefore, it is logical that a rigid follow-up, even later
n the postoperative course, is mandatory to enhance the
uccess rate of the procedure. Late arrhythmias during the
ollow-up phase should be dealt with in a uniform way to
nhance success and improve the outcome of patients.7,8 An
pen discussion is necessary to develop a protocol for
ollow-up for patients after the maze procedure.
In summary, this study shows that the surgical treatment
f AF can be effective in patients with risk factors for
ailure. The success rate can be improved by active treat-
ent of the arrhythmia when it reoccurs. Follow-up clinics
or patients after the maze procedure should be established
o facilitate a more uniform approach to the care of these
atients.
tudy Limitations
n this study we present the results of the maze procedure
n a unique subgroup of patients with high risk of failure.
he study size is fairly small, and the follow-up is not as
ong as in other studies.9 Because of the nature of the
tudy, some of the predictors for the different end points
f the study may be different from those in the current
iterature.
Our follow-up included an early Holter monitoring (3
onths after surgery) and repeated electrocardiogram. This
ethod of rhythm monitoring is common, although very
imited. We are pleased with the high rate of initial Holter
onitoring; however, on the basis of the recent publication
e believe that future reports should include a longer mon-
toring period using event recorders or long-term Holter
onitoring devices.20
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CDiscussion
r. Millar. I congratulate the authors in presenting a group of
atients with the predicted worst outcome of atrial fibrillation
urgery, this being patients with rheumatic fever and/or enlarged
eft atria. I have a few questions.
Did you encounter in any of these patients, this is obviously a
elected group, those with heavily fibrotic or calcified left atria,
nd did you include or exclude those patients from this group?
Dr. Ad. In general, we are very aggressive in treating atrial
brillation surgically and we do operate on every patient with a
ignificant atrial fibrillation history for longer than 3 months. The
nly real contraindication for performing the maze procedure is
alcified left atrium. We may always argue, however, about the
uccess rate of the procedure when performed in patients with
nlarged and fibrotic left atrium. In this series patients with fibrotic
trium were included; I don’t have the numbers, since we never
end atrial tissue for pathology.
Dr. Millar. The second question, you reported 98% of your
atients were free of atrial fibrillation on discharge from the
ospital, yet in the first three months 53% had recurrent atrial
rrhythmias during that first three-month period. Are all patients
n amiodarone postop? For how long? How aggressive are you
ith cardioversion during the hospital stay itself?
Dr. Ad. I believe that your question is very important, and I am
lad you have asked it. In recent months we changed our practice
nd do discharge more patients with atrial arrhythmia provided
hey are rate controlled, simply because we found that the patients
an go home earlier and that the success rate of the cardioversion
s much higher if performed three to six weeks postoperatively. All
he patients are being discharged on amiodarone or other type of
nti-arrhythmic drug and are kept on it for three to six months.
Dr. Millar. In this 53% that had recurrent atrial fibrillation
uring the first three months, how do you alter your antiarrhythmic
reatment if they’re all on amiodarone to begin with? Do you give
hem the rebolus or increase the dosage or just go to cardioversion?
Dr. Ad. Basically, we won’t change the amiodarone treatment.
e keep the patients on the drug; however, before cardioversion
e make sure that they are well loaded with it. In case of a failed
ardioversion the anti-arrhythmic would be changed following a
equired period of window. The second choice of drug is sotalol.
Dr. Millar. Thank you. Your paper really does encourage the
eed for long-term followup in patients with atrial arrhythmia
urgery. Too often our cardiology colleagues see them back in
trial fibrillation early and say, oh, it failed, that’s it, put them back
n Coumadin and forget about it. Unless we as surgeons educate
ur cardiology colleagues and/or follow these patients ourselves,
e will lose the opportunity to convert many of these back to sinus a
The Journal of Thoracicechanism. Often we are much closer than you think and even
hose that recur late, up to a year, often just restarting an antiar-
hythmic agent, they will convert spontaneously. This is what
ou’ve shown I agree wholeheartedly. There is a small group of
atients that have as you say atrial arrhythmias that are sinus
achycardias or are atrial flutter and these often can be managed
ery well by cooperation with our electrophysiology colleagues
ith a very minor ablative procedure. Often we miss getting high
nough in the superior or inferior vena cava, a very common place
or a flutter mechanism that can be ablated easily.
I congratulate you on your efforts and your emphasis on late
ollowup and persistence in trying to get these patients back into
inus rhythm. I thank the association for the opportunity to discuss
he paper.
Dr. Ad. Thank you.
Dr. Misbach. When I hear you say that the early postoperative
trial fibrillation is a predictor of late failure, that’s a little bit
ifferent than what I’ve been hearing at meetings in recent years.
o you think that this early recurrence actually changes what
appens later, that atrial fibrillation begets atrial fibrillation and
hat your aggressiveness or lack of aggressiveness that we might
ave in the first month after surgery has any effect on the long-
erm outcome, or is this simply a reflection of what remodeling has
lready occurred before the intervention?
Dr. Ad. I think that you brought up a very good point. This
roup of patients is unique, and I do believe that the more aggres-
ive we are in treating post-operative arrhythmia the better we are.
his may also be applied to other patients, since I believe that atrial
brillation serves as a final common pathway to quite a few
ifferent processes and it is to some extent a cardiomyopathy of
he atrial tissue. The problem is that right now we don’t know
nough to support any assumption. Based on our experience we
an say that you can keep more patients out of atrial fibrillation if
ou address the arrhythmia repeatedly throughout the post-opera-
ive period.
Dr. Misbach. That was really—my next question is, if you’ve
ad them on amiodarone routinely postoperatively and we’ve had
ay 1 or 2 cardioversions and then you add another drug such as
otalol and you discharge them in atrial fibrillation, how long
ould you wait before cardioverting them again? One week? One
onth?
Dr. Ad. About 4 to 6 weeks. Usually I use amiodarone to save
ospital days, since with sotalol you have to wait 72 hours to make
ure that no long QT interval was developed. As mentioned, if they
ail cardioversion on drug A we do treat them with a second drug
nd cardiovert them when loaded.
and Cardiovascular Surgery ● Volume 131, Number 5 1079
